{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:13:43Z","timestamp":1783948423539,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070153"],"award-info":[{"award-number":["82070153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06418-7","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:53:15Z","timestamp":1748303595000},"page":"3235-3250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia"],"prefix":"10.1007","volume":"104","author":[{"given":"Kai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-Hong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-0946","authenticated-orcid":false,"given":"Ya-Zhen","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"6418_CR1","doi-asserted-by":"publisher","unstructured":"Newell LF, Cook RJ (2021) Advances in acute myeloid leukemia. BMJ (Clinical Res ed) 375(n2026). https:\/\/doi.org\/10.1136\/bmj.n2026","DOI":"10.1136\/bmj.n2026"},{"issue":"12","key":"6418_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, R\u00f6llig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, L\u00f6wenberg B (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"3","key":"6418_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM (2023) Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(3):502\u2013526. https:\/\/doi.org\/10.1002\/ajh.26822","journal-title":"Am J Hematol"},{"issue":"10393","key":"6418_CR4","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH (2023) Acute myeloid leukaemia. Lancet (London England) 401(10393):2073\u20132086. https:\/\/doi.org\/10.1016\/s0140-6736(23)00108-3","journal-title":"Lancet (London England)"},{"issue":"1","key":"6418_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-021-00265-0","volume":"9","author":"R Guo","year":"2021","unstructured":"Guo R, L\u00fc M, Cao F, Wu G, Gao F, Pang H, Li Y, Zhang Y, Xing H, Liang C, Lyu T, Du C, Li Y, Guo R, Xie X, Li W, Liu D, Song Y, Jiang Z (2021) Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment. Biomark Res 9(1):15. https:\/\/doi.org\/10.1186\/s40364-021-00265-0","journal-title":"Biomark Res"},{"key":"6418_CR6","doi-asserted-by":"publisher","unstructured":"Rutella S, Vadakekolathu J, Mazziotta F, Reeder S, Yau TO, Mukhopadhyay R, Dickins B, Altmann H, Kramer M, Knaus HA, Blazar BR, Radojcic V, Zeidner JF, Arruda A, Wang B, Abbas HA, Minden MD, Tasian SK, Bornh\u00e4user M, Gojo I, Luznik L (2022) Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia. J Clin Investig 132(21). https:\/\/doi.org\/10.1172\/jci159579","DOI":"10.1172\/jci159579"},{"issue":"21","key":"6418_CR7","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint Blockade. Cell 184(21):5309\u20135337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020","journal-title":"Cell"},{"issue":"1","key":"6418_CR8","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T (2021) Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Therapy 6(1):72. https:\/\/doi.org\/10.1038\/s41392-020-00449-4","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"6418_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11912-019-0781-7","volume":"21","author":"M Stahl","year":"2019","unstructured":"Stahl M, Goldberg AD (2019) Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets. Curr Oncol Rep 21(4):37. https:\/\/doi.org\/10.1007\/s11912-019-0781-7","journal-title":"Curr Oncol Rep"},{"key":"6418_CR10","doi-asserted-by":"publisher","unstructured":"Damiani D, Tiribelli M (2023) Checkpoint inhibitors in acute myeloid leukemia. Biomedicines 11(6). https:\/\/doi.org\/10.3390\/biomedicines11061724","DOI":"10.3390\/biomedicines11061724"},{"issue":"12","key":"6418_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux K, Delgoffe GM (2021) Metabolic barriers to cancer immunotherapy. Nat Rev Immunol 21(12):785\u2013797. https:\/\/doi.org\/10.1038\/s41577-021-00541-y","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"6418_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L (2021) Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer 21(5):298\u2013312. https:\/\/doi.org\/10.1038\/s41568-021-00339-z","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"6418_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.it.2013.10.001","volume":"35","author":"A Schietinger","year":"2014","unstructured":"Schietinger A, Greenberg PD (2014) Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 35(2):51\u201360. https:\/\/doi.org\/10.1016\/j.it.2013.10.001","journal-title":"Trends Immunol"},{"issue":"1","key":"6418_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-018-0636-y","volume":"11","author":"L Xu","year":"2018","unstructured":"Xu L, Yao D, Tan J, He Z, Yu Z, Chen J, Luo G, Wang C, Zhou F, Zha X, Chen S, Li Y (2018) Memory T cells skew toward terminal differentiation in the CD8\u2009+\u2009T cell population in patients with acute myeloid leukemia. J Hematol Oncol 11(1):93. https:\/\/doi.org\/10.1186\/s13045-018-0636-y","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6418_CR15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","volume":"10","author":"M Noviello","year":"2019","unstructured":"Noviello M, Manfredi F, Ruggiero E, Perini T, Oliveira G, Cortesi F, De Simone P, Toffalori C, Gambacorta V, Greco R, Peccatori J, Casucci M, Casorati G, Dellabona P, Onozawa M, Teshima T, Griffioen M, Halkes CJM, Falkenburg JHF, St\u00f6lzel F, Altmann H, Bornh\u00e4user M, Waterhouse M, Zeiser R, Finke J, Cieri N, Bondanza A, Vago L, Ciceri F, Bonini C (2019) Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun 10(1):1065. https:\/\/doi.org\/10.1038\/s41467-019-08871-1","journal-title":"Nat Commun"},{"issue":"7","key":"6418_CR16","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Y Kong","year":"2015","unstructured":"Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H (2015) PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood cancer J 5(7):e330. https:\/\/doi.org\/10.1038\/bcj.2015.58","journal-title":"Blood cancer J"},{"key":"6418_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","volume":"8","author":"FM Schnorfeil","year":"2015","unstructured":"Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M (2015) T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 8:93. https:\/\/doi.org\/10.1186\/s13045-015-0189-2","journal-title":"J Hematol Oncol"},{"key":"6418_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40364-020-0185-8","volume":"8","author":"J Tan","year":"2020","unstructured":"Tan J, Yu Z, Huang J, Chen Y, Huang S, Yao D, Xu L, Lu Y, Chen S, Li Y (2020) Increased PD-1\u2009+\u2009Tim-3\u2009+\u2009exhausted T cells in bone marrow May influence the clinical outcome of patients with AML. Biomark Res 8:6. https:\/\/doi.org\/10.1186\/s40364-020-0185-8","journal-title":"Biomark Res"},{"issue":"1","key":"6418_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s40425-019-0611-3","volume":"7","author":"P Dama","year":"2019","unstructured":"Dama P, Tang M, Fulton N, Kline J, Liu H (2019) Gal9\/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer 7(1):175. https:\/\/doi.org\/10.1186\/s40425-019-0611-3","journal-title":"J Immunother Cancer"},{"key":"6418_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","volume":"190","author":"M Wang","year":"2018","unstructured":"Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G, Lin Q, Xu X, Leavenworth JW, Shen E (2018) CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol (Orlando Fla) 190:64\u201373. https:\/\/doi.org\/10.1016\/j.clim.2017.08.021","journal-title":"Clin Immunol (Orlando Fla)"},{"issue":"1","key":"6418_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-017-0414-2","volume":"10","author":"YZ Qin","year":"2017","unstructured":"Qin YZ, Wang Y, Xu LP, Zhang XH, Chen H, Han W, Chen YH, Wang FR, Wang JZ, Chen Y, Mo XD, Zhao XS, Chang YJ, Liu KY, Huang XJ (2017) The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol 10(1):44. https:\/\/doi.org\/10.1186\/s13045-017-0414-2","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6418_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.bbmt.2017.09.002","volume":"24","author":"YZ Qin","year":"2018","unstructured":"Qin YZ, Chen Y, Xu LP, Wang Y, Zhang XH, Chen H, Zhao XS, Liu KY, Huang XJ (2018) Outcome and minimal residual disease monitoring in patients with t(16;21) acute myelogenous leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 24(1):163\u2013168. https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.002","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"6418_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/bjh.16526","volume":"190","author":"YL Zhou","year":"2020","unstructured":"Zhou YL, Wu LX, Peter Gale R, Wang ZL, Li JL, Jiang H, Jiang Q, Jiang B, Cao SB, Lou F, Sun Y, Wang CC, Liu YR, Wang Y, Chang YJ, Xu LP, Zhang XH, Liu KY, Ruan GR, Huang XJ (2020) Mutation topography and risk stratification for de Novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD). Br J Haematol 190(2):274\u2013283. https:\/\/doi.org\/10.1111\/bjh.16526","journal-title":"Br J Haematol"},{"issue":"2","key":"6418_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00277-008-0591-8","volume":"88","author":"GR Ruan","year":"2009","unstructured":"Ruan GR, Li JL, Qin YZ, Li LD, Xie M, Chang Y, Zhang Y, Liu YR, Jiang B, Chen SS, Huang XJ (2009) Nucleophosmin mutations in Chinese adults with acute myelogenous leukemia. Ann Hematol 88(2):159\u2013166. https:\/\/doi.org\/10.1007\/s00277-008-0591-8","journal-title":"Ann Hematol"},{"issue":"5","key":"6418_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/ijlh.13864","volume":"44","author":"N Xu","year":"2022","unstructured":"Xu N, Lai YY, Chen WM, Jiang H, Wang Y, Wang X, Zhao XS, Huang XJ, Jiang Q, Qin YZ (2022) Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype. Int J Lab Hematol 44(5):892\u2013899. https:\/\/doi.org\/10.1111\/ijlh.13864","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"6418_CR26","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1007\/s00277-024-06001-6","volume":"103","author":"W Duan","year":"2024","unstructured":"Duan W, Jia J, Wang J, Liu X, Yu W, Zhu X, Zhao T, Jiang Q, Ruan G, Zhao X, Shi H, Chang Y, Wang Y, Xu L, Zhang X, Huang X, Jiang H (2024) Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a\u2009<\u20093log reduction of MRD2 predicted poor survival. Ann Hematol 103(11):4525\u20134535. https:\/\/doi.org\/10.1007\/s00277-024-06001-6","journal-title":"Ann Hematol"},{"issue":"1","key":"6418_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"XH Zhang","year":"2021","unstructured":"Zhang XH, Chen J, Han MZ, Huang H, Jiang EL, Jiang M, Lai YR, Liu DH, Liu QF, Liu T, Ren HY, Song YP, Sun ZM, Tang XW, Wang JM, Wu DP, Xu LP, Zhang X, Zhou DB, Huang XJ (2021) The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol 14(1):145. https:\/\/doi.org\/10.1186\/s13045-021-01159-2","journal-title":"J Hematol Oncol"},{"issue":"1","key":"6418_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nprot.2012.143","volume":"8","author":"E Lugli","year":"2013","unstructured":"Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, Roederer M (2013) Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc 8(1):33\u201342. https:\/\/doi.org\/10.1038\/nprot.2012.143","journal-title":"Nat Protoc"},{"issue":"4","key":"6418_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, L\u00f6wenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"6418_CR30","doi-asserted-by":"publisher","unstructured":"Tang Q, Zhao S, Zhou N, He J, Zu L, Liu T, Song Z, Chen J, Peng L, Xu S (2023) PD\u20131\/PD\u2013L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review). Int J Oncol 62(4). https:\/\/doi.org\/10.3892\/ijo.2023.5497","DOI":"10.3892\/ijo.2023.5497"},{"issue":"9","key":"6418_CR31","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/jci80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X (2015) Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig 125(9):3384\u20133391. https:\/\/doi.org\/10.1172\/jci80011","journal-title":"J Clin Investig"},{"issue":"7","key":"6418_CR32","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N, Alotaibi AS, B\u00fccklein V, Subklewe M (2021) T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35(7):1843\u20131863. https:\/\/doi.org\/10.1038\/s41375-021-01253-x","journal-title":"Leukemia"},{"key":"6418_CR33","doi-asserted-by":"publisher","unstructured":"Abaza Y, Zeidan AM (2022) Immune checkpoint Inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells 11(14). https:\/\/doi.org\/10.3390\/cells11142249","DOI":"10.3390\/cells11142249"},{"issue":"12","key":"6418_CR34","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1073\/pnas.1100551108","volume":"108","author":"M Jan","year":"2011","unstructured":"Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 108(12):5009\u20135014. https:\/\/doi.org\/10.1073\/pnas.1100551108","journal-title":"Proc Natl Acad Sci USA"},{"key":"6418_CR35","doi-asserted-by":"publisher","first-page":"618710","DOI":"10.3389\/fimmu.2021.618710","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Chen J, Wang M, Zhang L, Yu L (2021) One stone, two birds: the roles of Tim-3 in acute myeloid leukemia. Front Immunol 12:618710. https:\/\/doi.org\/10.3389\/fimmu.2021.618710","journal-title":"Front Immunol"},{"key":"6418_CR36","doi-asserted-by":"publisher","unstructured":"Daver N, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Ning J, Xiao L, Juliana L, Kornblau SM, Konopleva M, Andreeff M, Flores W, Bueso-Ramos CE, Somani N, Blando J, Allison J, Kantarjian HM, Sharma P (2016) Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). Blood 128(22):2900\u20132900. https:\/\/doi.org\/10.1182\/blood.V128.22.2900.2900","DOI":"10.1182\/blood.V128.22.2900.2900"},{"issue":"9","key":"6418_CR37","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/cncr.31896","volume":"125","author":"P Williams","year":"2019","unstructured":"Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG (2019) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 125(9):1470\u20131481. https:\/\/doi.org\/10.1002\/cncr.31896","journal-title":"Cancer"},{"issue":"18","key":"6418_CR38","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R (2018) Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci USA 115(18):4749\u20134754. https:\/\/doi.org\/10.1073\/pnas.1718217115","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"6418_CR39","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1158\/1078-0432.Ccr-19-3003","volume":"26","author":"L Tang","year":"2020","unstructured":"Tang L, Wu J, Li CG, Jiang HW, Xu M, Du M, Yin Z, Mei H, Hu Y (2020) Characterization of immune dysfunction and identification of prognostic immune-Related risk factors in acute myeloid leukemia. Clin cancer Research: Official J Am Association Cancer Res 26(7):1763\u20131772. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3003","journal-title":"Clin cancer Research: Official J Am Association Cancer Res"},{"issue":"1","key":"6418_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s40001-023-01352-8","volume":"28","author":"Y Ruan","year":"2023","unstructured":"Ruan Y, Wang J, Zhang Q, Wang H, Li C, Xu X, Zhai Z (2023) Clinical implications of aberrant PD-1 expression for acute leukemia prognosis. Eur J Med Res 28(1):383. https:\/\/doi.org\/10.1186\/s40001-023-01352-8","journal-title":"Eur J Med Res"},{"issue":"1","key":"6418_CR41","doi-asserted-by":"publisher","first-page":"15658","DOI":"10.1038\/s41598-023-42700-2","volume":"13","author":"W Huang","year":"2023","unstructured":"Huang W, Zheng S, Wang Q, Zhao N, Long Z (2023) Identification and validation of a prognostic risk-scoring model based on the level of TIM-3 expression in acute myeloid leukemia. Sci Rep 13(1):15658. https:\/\/doi.org\/10.1038\/s41598-023-42700-2","journal-title":"Sci Rep"},{"issue":"7","key":"6418_CR42","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1002\/cam4.5549","volume":"12","author":"Z Wu","year":"2023","unstructured":"Wu Z, Ou J, Liu N, Wang Z, Chen J, Cai Z, Liu X, Yu X, Dai M, Zhou H (2023) Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia. Cancer Med 12(7):8956\u20138969. https:\/\/doi.org\/10.1002\/cam4.5549","journal-title":"Cancer Med"},{"issue":"1","key":"6418_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/10428194.2021.1966785","volume":"63","author":"J Wang","year":"2022","unstructured":"Wang J, Yang L, Dao FT, Wang YZ, Chang Y, Xu N, Chen WM, Jiang Q, Jiang H, Liu YR, Qin YZ (2022) Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia. Leuk Lymphoma 63(1):152\u2013161. https:\/\/doi.org\/10.1080\/10428194.2021.1966785","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6418_CR44","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3324\/haematol.2019.225003","volume":"105","author":"M Bill","year":"2020","unstructured":"Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mr\u00f3zek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield CD (2020) Mutations associated with a 17-gene leukemia stem cell score and the score\u2019s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. Haematologica 105(3):721\u2013729. https:\/\/doi.org\/10.3324\/haematol.2019.225003","journal-title":"Haematologica"},{"key":"6418_CR45","doi-asserted-by":"publisher","first-page":"107965","DOI":"10.1016\/j.intimp.2021.107965","volume":"99","author":"L Yang","year":"2021","unstructured":"Yang L, Feng Y, Wang S, Jiang S, Tao L, Li J, Wang X (2021) Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia. Int Immunopharmacol 99:107965. https:\/\/doi.org\/10.1016\/j.intimp.2021.107965","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"6418_CR46","doi-asserted-by":"publisher","first-page":"1889822","DOI":"10.1080\/2162402x.2021.1889822","volume":"10","author":"J Rakova","year":"2021","unstructured":"Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D, Kline JP, Racil Z, Galluzzi L, Spisek R, Fucikova J (2021) TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. Oncoimmunology 10(1):1889822. https:\/\/doi.org\/10.1080\/2162402x.2021.1889822","journal-title":"Oncoimmunology"},{"key":"6418_CR47","doi-asserted-by":"publisher","unstructured":"Sun K, Shi ZY, Xie DH, Wang YZ, Jiang H, Jiang Q, Huang XJ, Qin YZ (2024) The functional role and prognostic significance of TIM-3 expression on NK cells in the diagnostic bone marrows in acute myeloid leukemia. Biomedicines 12(12). https:\/\/doi.org\/10.3390\/biomedicines12122717","DOI":"10.3390\/biomedicines12122717"},{"key":"6418_CR48","doi-asserted-by":"publisher","first-page":"763773","DOI":"10.3389\/fmed.2021.763773","volume":"8","author":"F Brauneck","year":"2021","unstructured":"Brauneck F, Weimer P, Schulze Zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W (2021) Bone Marrow-Resident V\u03b41 T cells Co-express TIGIT with PD-1, TIM-3 or CD39 in AML and myeloma. Front Med 8:763773. https:\/\/doi.org\/10.3389\/fmed.2021.763773","journal-title":"Front Med"},{"key":"6418_CR49","doi-asserted-by":"publisher","unstructured":"Kim YJ, Kwag D, Kim BR, Son H, Park S, Kim HJ, Cho BS (2024) Characterization of the bone marrow lymphoid microenvironment and discovery of prognostic Immune-Related factors in acute myeloid leukemia. Int J Mol Sci 25(23). https:\/\/doi.org\/10.3390\/ijms252313039","DOI":"10.3390\/ijms252313039"},{"key":"6418_CR50","doi-asserted-by":"publisher","first-page":"106122","DOI":"10.1016\/j.intimp.2019.106122","volume":"80","author":"K Wu","year":"2020","unstructured":"Wu K, Feng J, Xiu Y, Li Z, Lin Z, Zhao H, Zeng H, Xia W, Yu L, Xu B (2020) V\u03b42 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients. Int Immunopharmacol 80:106122. https:\/\/doi.org\/10.1016\/j.intimp.2019.106122","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"6418_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","volume":"13","author":"C Chen","year":"2020","unstructured":"Chen C, Liang C, Wang S, Chio CL, Zhang Y, Zeng C, Chen S, Wang C, Li Y (2020) Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol 13(1):28. https:\/\/doi.org\/10.1186\/s13045-020-00853-x","journal-title":"J Hematol Oncol"},{"key":"6418_CR52","doi-asserted-by":"publisher","unstructured":"Brodsk\u00e1 B, Otev\u0159elov\u00e1 P, \u0160\u00e1lek C, Fuchs O, Ga\u0161ov\u00e1 Z, Ku\u017eelov\u00e1 K (2019) High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations. Int J Mol Sci 20(11). https:\/\/doi.org\/10.3390\/ijms20112823","DOI":"10.3390\/ijms20112823"},{"key":"6418_CR53","doi-asserted-by":"publisher","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M G\u00f3mez-Llobell","year":"2022","unstructured":"G\u00f3mez-Llobell M, Peleteiro Ra\u00edndo A, Climent Medina J, G\u00f3mez Centuri\u00f3n I, Mosquera Orgueira A (2022) Immune checkpoint inhibitors in acute myeloid leukemia: A Meta-Analysis. Front Oncol 12:882531. https:\/\/doi.org\/10.3389\/fonc.2022.882531","journal-title":"Front Oncol"},{"issue":"4","key":"6418_CR54","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1158\/2643-3230.Bcd-23-0202","volume":"5","author":"C Restelli","year":"2024","unstructured":"Restelli C, Ruella M, Paruzzo L, Tarella C, Pelicci PG, Colombo E (2024) Recent advances in Immune-Based therapies for acute myeloid leukemia. Blood cancer Discovery 5(4):234\u2013248. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-23-0202","journal-title":"Blood cancer Discovery"},{"key":"6418_CR55","doi-asserted-by":"publisher","unstructured":"Zeidan AM, Miyazaki Y, Platzbecker U, Malek K, Niolat J, Kiertsman F, Fenaux P (2019) A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1. Blood 134(Supplement_1):4259\u20134259. https:\/\/doi.org\/10.1182\/blood-2019-127041","DOI":"10.1182\/blood-2019-127041"},{"key":"6418_CR56","doi-asserted-by":"publisher","unstructured":"Zeidan AM, Cavenagh J, Voso MT, Taussig D, Tormo M, Boss I, Copeland WB, Gray VE, Previtali A, O\u2019Connor T, Rose S, Beach C, Silverman LR (2019) Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study. Blood 134(Supplement_1):829\u2013829. https:\/\/doi.org\/10.1182\/blood-2019-122896","DOI":"10.1182\/blood-2019-122896"},{"issue":"3","key":"6418_CR57","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.Cd-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H (2019) Efficacy, safety, and biomarkers of response to Azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, Open-Label, phase II study. Cancer Discov 9(3):370\u2013383. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0774","journal-title":"Cancer Discov"},{"issue":"22","key":"6418_CR58","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/bloodadvances.2021004583","volume":"5","author":"HA Abbas","year":"2021","unstructured":"Abbas HA, Alaniz Z, Mackay S, Cyr M, Zhou J, Issa GC, Alfayez M, Matthews J, Kornblau SM, Jabbour E, Garcia-Manero G, Konopleva M, Andreeff M, Daver N (2021) Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti-PD-1-based therapy. Blood Adv 5(22):4569\u20134574. https:\/\/doi.org\/10.1182\/bloodadvances.2021004583","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06418-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06418-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:01:08Z","timestamp":1753171268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06418-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6418"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06418-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of Peking University People\u2019s Hospital. All subjects provided written informed consent in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}